Literature DB >> 12463596

Follicular lymphoma in Osaka, Japan: histological features and chronological change.

Hajime Miyazato1, Shin-ichi Nakatsuka, Itsuko Miyanaga, Hitoshi Hanamoto, Yoichi Tatsumi, Mitsuhiro Matsuda, Yasuhiro Maeda, Akihisa Kanamaru, Katsuyuki Aozasa.   

Abstract

Follicular lymphoma (FL) is defined as a neoplastic proliferation of follicle center cells with varying follicular areas. To learn the time trend of FL in the Osaka area, an adult T-cell leukemia/lymphoma (ATL) nonendemic area of Japan, we examined the frequency of FL among all non-Hodgkin's lymphomas (NHLs) during the period 1964 to 1987 (n = 1,000) and 1999 to 2001 (n = 659). The frequency of FL with varying follicular areas increased from 1964-1987 to 1999-2001. There was a significant difference in frequency of total cases of FL (14.2% versus 18.8%) (P < .05) and FL with no to 25% follicular area (2.3% versus 5.0%) (P < .01). According to the Berard criteria, cytologic grade of FL was defined by counting the number of centroblasts (CB) in 10 neoplastic follicles as follow: < or = 5 CB per high power field (HPF), grade 1; 6-15 CB, grade 2; >15 CB, grade 3. Immunohistochemical staining with monoclonal antibodies for bcl-2 and CD10 was performed. There was an inverse correlation between follicular area and cytological grade (P < .0001) and bcl-2 expression and cytological grade (P < .01). That is, the larger the follicular area in cases with a lower cytological grade, the stronger was bcl-2 expression in a lower cytological grade. There was a significant correlation between follicular area and stage of disease (P < .05). That is, the follicular area was larger in cases in an advanced stage. This study showed the increase in frequency of FL in Osaka, Japan. Change of lifestyle in Japan may be one of the causative factors for the increase.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12463596     DOI: 10.1007/bf02982692

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  15 in total

1.  CD10 antigen expression correlates with the t(14;18)(q32;q21) major breakpoint region in diffuse large B-cell lymphoma.

Authors:  J M Fang; W G Finn; J W Hussong; C L Goolsby; A R Cubbon; D Variakojis
Journal:  Mod Pathol       Date:  1999-03       Impact factor: 7.842

2.  Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project.

Authors:  J R Anderson; J O Armitage; D D Weisenburger
Journal:  Ann Oncol       Date:  1998-07       Impact factor: 32.976

3.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.

Authors: 
Journal:  Blood       Date:  1997-06-01       Impact factor: 22.113

4.  Prognostic factors and a predictive model of follicular lymphoma: a 25-year study at a single institution in Japan.

Authors:  N Katsumata; Y Matsuno; H Nakayama; T Takenaka; Y Kobayashi; K Takeyama; M Narabayashi; T Fukushima; T Yokozawa; M Nakata; K Tajima; H Ikeda; K Tobinai
Journal:  Jpn J Clin Oncol       Date:  1996-12       Impact factor: 3.019

5.  Immunohistochemical detection of p53, bcl-2, and retinoblastoma proteins in follicular lymphoma.

Authors:  P L Nguyen; L R Zukerberg; W F Benedict; N L Harris
Journal:  Am J Clin Pathol       Date:  1996-05       Impact factor: 2.493

6.  Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method.

Authors:  R B Mann; C W Berard
Journal:  Hematol Oncol       Date:  1983 Apr-Jun       Impact factor: 5.271

7.  Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma.

Authors:  M Llanos; H Alvarez-Argüelles; R Alemán; J Oramas; L Diaz-Flores; N Batista
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

8.  Assessment of prognostic factors in follicular lymphoma patients.

Authors:  E Kondo; M Ogura; Y Kagami; H Taji; K Miura; T Takeuchi; S Maeda; S Asakura; R Suzuki; S Nakamura; Y Morishima
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

9.  Non-Hodgkin's lymphomas of follicular center cell type in Osaka, Japan.

Authors:  M Ohsawa; K Aozasa; T Tsujimura; H Ikeda; T Tsujimura
Journal:  Eur J Cancer Clin Oncol       Date:  1989-12

Review 10.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

View more
  3 in total

1.  Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project.

Authors:  Anamarija M Perry; Jacques Diebold; Bharat N Nathwani; Kenneth A MacLennan; Hans K Müller-Hermelink; Martin Bast; Eugene Boilesen; James O Armitage; Dennis D Weisenburger
Journal:  Haematologica       Date:  2016-06-27       Impact factor: 9.941

2.  Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial.

Authors:  Ken Ohmachi; Kensei Tobinai; Tomohiro Kinoshita; Takayuki Ishikawa; Kiyohiko Hatake; Satoshi Ichikawa; Ken Ohmine; Yuri Kamitsuji; Ilseung Choi; Takaaki Chou; Kunihiro Tsukasaki; Kyoya Kumagai; Masafumi Taniwaki; Toshiki Uchida; Yoshitaka Kikukawa; Kohmei Kubo; Keichiro Mihara; Norifumi Tsukamoto; Koji Izutsu; Isao Yoshida; Fumihiro Ishida; Noriko Usui; Shinsuke Iida; Tohru Murayama; Eisuke Ueda; Hiroshi Kuriki; Kiyoshi Ando
Journal:  Int J Hematol       Date:  2018-07-19       Impact factor: 2.490

3.  Analysis of follicular lymphoma by dual-color fluorescence in situ hybridization.

Authors:  Dakeun Lee; Jinwon Seo; YoungLyun Oh; Jinman Kim; YoungHyeh Ko
Journal:  Virchows Arch       Date:  2007-11-27       Impact factor: 4.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.